Bicara Therapeutics: HC Wainwright Downgrades to Buy, PT $41 from $44.
ByAinvest
Friday, May 16, 2025 7:17 am ET1min read
BCAT--
The price target reduction reflects a slight tempering of optimism regarding Bicara Therapeutics' growth trajectory. Despite the downgrade, the "Buy" rating indicates that HC Wainwright & Co. remains bullish on the company's prospects. Investors are advised to consider this information when evaluating their investment decisions.
Wall Street analysts have forecasted varying price targets for Bicara Therapeutics Inc (BCRT). The average target price, based on the consensus of seven analysts, is $39.14, with a high estimate of $42.00 and a low estimate of $33.00. This average target price implies an upside of 84.42% from the current price of $19.89.
The consensus recommendation from eight brokerage firms is currently 1.6, indicating an "Outperform" status. This rating scale ranges from 1 to 5, where 1 signifies a "Strong Buy" and 5 denotes a "Sell."
Investors should closely monitor Bicara Therapeutics' performance and any updates from HC Wainwright & Co. to make informed decisions.
References:
[1] https://www.gurufocus.com/news/2866140/enliven-therapeutics-elvn-target-price-raised-by-hc-wainwright-co-elvn-stock-news
BCAX--
HNI--
Bicara Therapeutics: HC Wainwright Downgrades to Buy, PT $41 from $44.
Bicara Therapeutics (BCRT) has received a mixed signal from HC Wainwright & Co. The firm has downgraded its rating for Bicara Therapeutics from "Buy" to "Buy" while revising the price target from $44.00 to $41.00. The downgrade and adjustment were announced on May 16, 2025, by Robert Burns, an analyst at HC Wainwright & Co.The price target reduction reflects a slight tempering of optimism regarding Bicara Therapeutics' growth trajectory. Despite the downgrade, the "Buy" rating indicates that HC Wainwright & Co. remains bullish on the company's prospects. Investors are advised to consider this information when evaluating their investment decisions.
Wall Street analysts have forecasted varying price targets for Bicara Therapeutics Inc (BCRT). The average target price, based on the consensus of seven analysts, is $39.14, with a high estimate of $42.00 and a low estimate of $33.00. This average target price implies an upside of 84.42% from the current price of $19.89.
The consensus recommendation from eight brokerage firms is currently 1.6, indicating an "Outperform" status. This rating scale ranges from 1 to 5, where 1 signifies a "Strong Buy" and 5 denotes a "Sell."
Investors should closely monitor Bicara Therapeutics' performance and any updates from HC Wainwright & Co. to make informed decisions.
References:
[1] https://www.gurufocus.com/news/2866140/enliven-therapeutics-elvn-target-price-raised-by-hc-wainwright-co-elvn-stock-news
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet